WO2016163764A3 - Stabilized preparation of interferon beta variant - Google Patents

Stabilized preparation of interferon beta variant Download PDF

Info

Publication number
WO2016163764A3
WO2016163764A3 PCT/KR2016/003632 KR2016003632W WO2016163764A3 WO 2016163764 A3 WO2016163764 A3 WO 2016163764A3 KR 2016003632 W KR2016003632 W KR 2016003632W WO 2016163764 A3 WO2016163764 A3 WO 2016163764A3
Authority
WO
WIPO (PCT)
Prior art keywords
stabilized
pharmaceutical preparation
interferon beta
beta variant
poloxamer
Prior art date
Application number
PCT/KR2016/003632
Other languages
French (fr)
Korean (ko)
Other versions
WO2016163764A2 (en
Inventor
신영기
박상호
송경
이희정
곽은혜
장은진
정성훈
김남아
Original Assignee
에이비온 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160042320A external-priority patent/KR101781945B1/en
Application filed by 에이비온 주식회사 filed Critical 에이비온 주식회사
Publication of WO2016163764A2 publication Critical patent/WO2016163764A2/en
Publication of WO2016163764A3 publication Critical patent/WO2016163764A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta

Abstract

The present invention relates to a stabilized pharmaceutical preparation of R27T comprising a human interferon beta variant (R27T), an acetic acid buffer solution, arginine, mannitol, poloxamer 188, and methionine. The stabilized R27T pharmaceutical preparation according to the present invention comprises an acetic acid buffer solution, arginine, mannitol, poloxamer 188, and methionine, and thereby inhibits formation of an aggregate of an R27T protein and enables long-period storage because of an improvement in thermodynamic and structural stability. Thus, it is expected that the stabilized R27T pharmaceutical preparation will be useful in prevention, improvement and treatment of multiple sclerosis, cancer, autoimmune diseases, viral infectious diseases, HIV infectious diseases, hepatitis C, rheumatoid arthritis, etc.
PCT/KR2016/003632 2015-04-07 2016-04-07 Stabilized preparation of interferon beta variant WO2016163764A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20150049200 2015-04-07
KR10-2015-0049200 2015-04-07
KR1020160042320A KR101781945B1 (en) 2015-04-07 2016-04-06 Stabilized Formulations of Interferon beta Mutant
KR10-2016-0042320 2016-04-06

Publications (2)

Publication Number Publication Date
WO2016163764A2 WO2016163764A2 (en) 2016-10-13
WO2016163764A3 true WO2016163764A3 (en) 2016-12-01

Family

ID=57072138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003632 WO2016163764A2 (en) 2015-04-07 2016-04-07 Stabilized preparation of interferon beta variant

Country Status (1)

Country Link
WO (1) WO2016163764A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060009913A (en) * 2003-05-13 2006-02-01 아레스 트레이딩 에스.에이. Liquid stabilized protein formulations in coated pharmaceutical containers
KR20060039132A (en) * 2004-11-02 2006-05-08 삼성정밀화학 주식회사 Human interferon-beta mutein
KR20070030855A (en) * 2004-06-01 2007-03-16 아레스 트레이딩 에스.에이. Method of stabilizing proteins
KR20100099298A (en) * 2007-12-20 2010-09-10 메르크 세로노 에스. 에이. Peg-interferon-beta formulations
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060009913A (en) * 2003-05-13 2006-02-01 아레스 트레이딩 에스.에이. Liquid stabilized protein formulations in coated pharmaceutical containers
KR20070030855A (en) * 2004-06-01 2007-03-16 아레스 트레이딩 에스.에이. Method of stabilizing proteins
KR20060039132A (en) * 2004-11-02 2006-05-08 삼성정밀화학 주식회사 Human interferon-beta mutein
WO2006049423A1 (en) * 2004-11-02 2006-05-11 Samsung Fine Chemicals Co Ltd Human interferon-beta mutein
KR20100099298A (en) * 2007-12-20 2010-09-10 메르크 세로노 에스. 에이. Peg-interferon-beta formulations
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta

Also Published As

Publication number Publication date
WO2016163764A2 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
PH12018550148A1 (en) Hepatitis b antiviral agents
EA201890425A1 (en) ANTI-VIRUS PHOSPHODIAMIDE COMPOSITE BETA-AMINO ACID COMPOUNDS
FI3692040T3 (en) Chemical compounds
EA201591287A1 (en) VACCINES CONTAINING STABILIZED TRIMMERS OF THE HUMAN IMMUNODEFICIENCY VIRUS VIRUS, AND METHODS OF THEIR USE
CO2017010162A2 (en) Ss-d-2'-deoxy-2'-α-fluoro-2'-ß-c-substituted-2-modified-n6-substituted purine nucleotides for the treatment of hepatitis c virus
MX2020002191A (en) Hepatitis b antiviral agents.
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
WO2015042308A3 (en) Rna-based hiv inhibitors
HRP20211749T1 (en) Pentanoic acids substituted by pyrrolo-[2-3,b]pyrimidine-pyridines for the treatment of influenza viral infections
WO2015052543A3 (en) Malaria vaccination
EA200800467A1 (en) APPLICATION OF COMPLEX ETHERS OF HYDROXYBENZOIC ACID AND ANALOGUES FOR OBTAINING MEDICINES FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTION
EP3416675A4 (en) Treatment of hepatitis delta virus infection with interferon lambda
BR112015017966A2 (en) immunogenic compositions comprising silified virus and methods of use
MX2013011411A (en) Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases.
EP3840773A4 (en) Treatment of hepatitis delta virus infection with interferon lambda
HRP20200332T1 (en) Exenatide modifier and use thereof
WO2013021284A3 (en) Anti-il-6 vaccine composition
WO2016163764A3 (en) Stabilized preparation of interferon beta variant
WO2018066891A3 (en) Stabilized preparation of interferon beta variant
MY189021A (en) Peptides and uses therefor as antiviral agents
EP4279577A3 (en) Process
EA201790778A1 (en) PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION FROM HEPATITIS C
WO2020005189A3 (en) Solid oral pharmaceutical compositions comprising teriflunomide
EA201790991A1 (en) METHOD OF TREATMENT USING A PEGILATED INTERFERON
JP2016011272A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16776867

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 14/12/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 16776867

Country of ref document: EP

Kind code of ref document: A2